Glenmark Pharma: IGI to present ISB 2001 data at ASH Meeting

Ichnos Glenmark Innovation (IGI), a subsidiary of Glenmark Pharmaceuticals, will present updated clinical data for its investigational drug ISB 2001 (ABBV-2001) at the 68th American Society of Hematology (ASH) Annual Meeting. ISB 2001 is a first-in-class CD38 x BCMA x CD3 trispecific T-cell engager being developed for relapsed/refractory multiple myeloma (RRMM). The presentation will include longer follow-up data from the Phase 1 TRIgnite-1 study's dose-escalation phase and early results from dose-expansion cohorts in heavily pretreated patients. IGI, in partnership with AbbVie, is focused on advancing ISB 2001 as a potential new treatment option for RRMM patients.